Provided by Tiger Trade Technology Pte. Ltd.

SINOMAB BIO-B

1.075
-0.015-1.38%
Volume:1.24M
Turnover:1.32M
Market Cap:1.49B
PE:-10.79
High:1.105
Open:1.105
Low:1.060
Close:1.090
52wk High:2.740
52wk Low:0.990
Shares:1.39B
HK Float Shares:1.39B
Volume Ratio:1.15
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.100
ROE:-29.96%
ROA:-9.63%
PB:2.52
PE(LYR):-10.79
PS:223.52

Loading ...

Sinomab Bioscience Files Board, Board Committee and Management Disclosure List

Reuters
·
Jul 03

Sinomab Bioscience Appoints COO Fang Liang as Executive Director

Reuters
·
Jul 03

Sinomab Bioscience - Appoints Fang Liang as Executive Director Effective 3 July 2026

THOMSON REUTERS
·
Jul 03

SINOMAB BIO-B Appoints Xue Lei as Non-Executive Director

Stock News
·
Jun 12

SinoMab BioScience: AGM Resolutions Secure 100% Support; Lei Xue Named Non-Executive Director

Bulletin Express
·
Jun 12

Hong Kong Stock Movement | SINOMAB BIO-B Surges Over 25% in Late Trading on Robust Pipeline and High BD Potential

Stock News
·
Jun 11

Sinomab Bio-B Maintains 1.39 Billion Issued Shares and Public Float Compliance in May 2026 Return

Bulletin Express
·
Jun 04

SinoMab Presents Preclinical Study Data of Vitiligo, Alopecia Drug at Dermatology Conference

MT Newswires Live
·
May 14

Revised Title

Stock News
·
May 14

Sinomab Bioscience posts unchanged share capital and maintains public float in April 2026 monthly return

Bulletin Express
·
May 06

SinoMab BioScience releases 2025 ESG report

Reuters
·
Apr 27

SinoMab BioScience unveils 2026 AGM agenda: board changes, 10% share buy-back mandate and 20% issuance limit

Bulletin Express
·
Apr 27

SinoMab BioScience announces annual general meeting

Reuters
·
Apr 27

SinoMab BioScience publishes 2025 annual report

Reuters
·
Apr 27

君实生物(SINOMAB BIO-B)2025年显著减亏,股本增长强化资金实力

Bulletin Express
·
Apr 27

Sinomab Bioscience Maintains 1.39 Billion Outstanding Shares in March 2026, Grants 11.57 Million New Options

Bulletin Express
·
Apr 08

BRIEF-Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience

Reuters
·
Apr 03

Hainan Haiyao Says Co Plans to Unload up to 5% Stake in SinoMab BioScience Ltd

THOMSON REUTERS
·
Apr 03

SM17 Phase 2 Trial for Atopic Dermatitis Administers First Dose in China

Stock News
·
Apr 01

SinoMab doses first patient in China Phase 2 trial of SM17 for atopic dermatitis

Reuters
·
Apr 01